Enliven <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts
Enliven Therapeutics Inc. announced that it will present preliminary clinical data from the ongoing ENABLE Phase 1a/1b trial of ELVN-001, a selective active site inhibitor of BCR::ABL1, in chronic myeloid leukemia (CML) patients with atypical fusion transcripts at the 67th Annual American Society of Hematology $(ASH)$ 2025 Annual Meeting. The presentation is scheduled for December 7, 2025, in Orlando, Florida. According to the company, ELVN-001 demonstrated encouraging anti-CML activity in a heavily pretreated patient population, including those with the e13a3 fusion transcript, which is resistant to certain tyrosine kinase inhibitors. Detailed data will be available following the presentation on Enliven Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA13119) on November 03, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。